| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 500mg | |||
| 1g | |||
| Other Sizes |
| Targets |
Not well characterized; potential targets include Ras oncogene signaling, histone deacetylases (HDACs), and other cancer-related pathways.
|
|---|---|
| ln Vitro |
In vitro, (rac)-Antineoplaston A10 has been reported to exhibit anticancer activity against various cancer cell lines. It may induce differentiation and apoptosis in cancer cells. Quantitative in vitro activity data (IC50 values) is not detailed in publicly available sources.
|
| ln Vivo |
In vivo, (rac)-Antineoplaston A10 has been studied in animal models and early clinical trials for its antitumor effects. It has been investigated as a potential treatment for various cancers. Detailed dose-response data from controlled studies is limited.
|
| Enzyme Assay |
No specific cell-free assay protocol is detailed for (rac)-Antineoplaston A10. For antineoplastons, typical cell-free assays might include enzyme inhibition studies (e.g., HDAC inhibition) or receptor binding assays.
|
| Cell Assay |
Cellular activity is assessed in cancer cell lines. Cells are treated with (rac)-Antineoplaston A10, and endpoints include cell viability (MTT), apoptosis detection (flow cytometry), differentiation markers, and signaling pathway analysis (Western blot).
|
| Animal Protocol |
In vivo efficacy has been evaluated in animal models and clinical trials. (rac)-Antineoplaston A10 is administered via oral or intravenous routes. Endpoints include tumor response, survival, and biomarker analysis.
|
| ADME/Pharmacokinetics |
Molecular weight and formula are not readily available in public sources. Storage: typical for small-molecule compounds (desiccated, protected from light).
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is publicly available. As an investigational anticancer agent, standard toxicological studies would be required for drug development.
|
| References | |
| Additional Infomation |
(rac)-Antineoplaston A10 is an investigational compound that has been studied in clinical trials for cancer treatment, though it is not FDA-approved. It is part of the antineoplaston family developed for anticancer therapy. Its mechanisms are not fully characterized but may involve Ras pathway modulation and HDAC inhibition.
|
| Molecular Formula |
C13H14N2O3
|
|---|---|
| Molecular Weight |
246.26186
|
| Exact Mass |
246.1
|
| CAS # |
77658-84-5
|
| Related CAS # |
Antineoplaston A10;91531-30-5
|
| PubChem CID |
157096
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.27 g/cm3
|
| Boiling Point |
571.2ºC at 760 mmHg
|
| Index of Refraction |
1.584
|
| LogP |
0.87
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
18
|
| Complexity |
348
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1C(CCC(N1)=O)NC(CC2=CC=CC=C2)=O
|
| InChi Key |
OQGRFQCUGLKSAV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H14N2O3/c16-11-7-6-10(13(18)15-11)14-12(17)8-9-4-2-1-3-5-9/h1-5,10H,6-8H2,(H,14,17)(H,15,16,18)
|
| Chemical Name |
N-(2,6-dioxopiperidin-3-yl)-2-phenylacetamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0607 mL | 20.3037 mL | 40.6075 mL | |
| 5 mM | 0.8121 mL | 4.0607 mL | 8.1215 mL | |
| 10 mM | 0.4061 mL | 2.0304 mL | 4.0607 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
